查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年生物製药管的全球市场
市场调查报告书
商品编码
1272768

2023-2030 年生物製药管的全球市场

Global Biopharmaceutical Tubing Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球生物製药管市场预计将实现利润丰厚的增长，到 2022 年将达到 35.804 亿美元，到 2030 年将达到 66.742 亿美元。 预计在预测期内（2023-2030 年），生物製药管市场的复合年增长率为 8.3%。 预计在预测期内，铂固化硅胶管作为一种材料的推出和使用将成为生物製药调整市场的一个主要趋势。

因此，玩家有很好的机会以优质且具有成本效益的产品进入生物製药管材市场。 例如，2020 年 1 月，Watson-Marlow Fluid Technology Group (WMFTG) 推出了 BioPure 硅胶输送管，它为广泛的生物过程流体输送应用提供了安全、可靠且具有成本效益的解决方案。

Bio Pure 硅胶管是半透明且抗撕裂的。 设计用于製药和生物技术产品的製造过程。 用于製药和生物技术应用的管材具有一定的规格。 使用可提取化合物时，这些包括承受灭菌过程的能力和传达阳性测试结果的能力。

由于与其他材料相比具有易灭菌、纯度高、柔韧性好、无副作用等诸多优点，硅胶生物药管的使用率越来越高，受此因素影响，生物药管市场增速较高。 生物製药管材市场规模包括硅胶、金属、塑料等生物製药管材种类，以及在製药/生物製药、临床、研发等各个领域的应用。

市场动态

人口老龄化和战略举措推动生物製药管材市场增长

随着人口老龄化的加剧，生物製药管的全球市场正在扩大。 预期寿命的延长导致世界上老年人口不断增加。 根据世界卫生组织 (WHO) 的数据，世界 60 岁及以上人口的比例将从 2015 年的 12% 增加到 2050 年的 22%，几乎翻了一番。

根据联合国《世界人口老龄化报告》，2017 年全球 60 岁及以上人口有 9.62 亿，预计到 2050 年将达到约 21 亿。

此外，产品发布、收购、合併和合作伙伴关係等战略举措也将为市场带来利润丰厚的增长。 例如，2021 年 4 月，再生医学开发商 BioCardia, Inc. 与日本一家顶级生物技术公司就潜在的 BioCardia Helix 导管生物治疗输送产品达成协议。 这是使用具有特定细胞类型的 BioCardia 螺旋导管进行生物治疗药物心臟输送的非排他性全球许可。

对于製造商而言，扩大研发和技术突破带来了巨大的扩张机会。 生物製药管材越来越多地被製药和生物製药行业用于物质和材料的输送，因此生物製药管材的市场机会是巨大的。

研发和技术进步为製造商提供了有利的增长前景

生物製药管材在製药和生物製药公司中被广泛接受用于化合物和材料的运输，因此存在巨大的市场机会。 对硅胶和金属生物製药管等产品的需求将为製造商提供有利可图的增长选择。

硅胶管和软管可用于输送通常用于生物製药就地清洗 (CIP) 和 SIP（□□就地灭菌）操作的化学品。 用于製药和生物製药应用的管材具有一定的规格。 目前正在研究和开发各种类型的硅胶管，但在此之前，需要满足医疗领域的使用标准，例如无毒和清洁。

医用硅胶管必须无臭、无毒、无味。 此外，它不得倾向于促进细菌的生长。 因此，技术进步和不断增加的研究和开发正在促进市场的增长。

与使用生物製药管相关的缺点和限制

在加工含有动物成分或动物衍生化合物的产品时，大多数製药和生物製药公司都会遇到与动物成分及其对成品影响相关的问题。 管道材料有时会与工业化合物发生反应。

硅油也可能是一种危险材料。 硅油可能会与其他成分发生反应并残留在产品中。 在製药和生物技术领域，焊接不良和管内表面是腐蚀和污染的主要原因。

由于管道和管件占与产品流体接触表面积的 90%，因此这些部件的製造方式必须能够轻鬆、一致地进行高质量焊接，以实现无故障製造。我做到了。

有关此报告的更多信息 - 索取样本

COVID-19 影响分析

除了 COVID-19 前、COVID 和后 COVID 情景外，对 COVID-19 的分析还包括价格动态（大流行期间的价格变化，与 COVID 前情景的比较等）、供需谱（由于限制、封锁和事后问题导致的供需贸易变化）、政府举措（政府机构的市场、行业和部门激活举措）以及製造商的战略举措。

俄乌衝突分析

由于该地区的主要市场参与者数量较少，因此估计俄罗斯-乌克兰衝突对全球生物製药管市场的影响较小。 不过，原材料进出口的影响预计在预测期内对全球生物製药管市场的增长影响不大。

内容

第一章调查方法及范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 片段类型
  • 片段：按用途
  • 摘要：按地区

第四章市场动态

  • 影响因素
    • 主持人
      • 不断增加的老年人口和战略举措
      • 一次性系统 (SUS) 应用的扩展
    • 约束因素
      • 与使用生物製药试管相关的缺点或限制
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 硅胶
  • 塑料
  • 金属

第 8 章应用

  • 製药和生物製药
  • 临床领域
  • 用于研究和开发
  • 诊断

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第11章公司简介

  • W. L. Gore and Associates, Inc.
    • 公司概况
    • 产品组合和概述
    • 财务摘要
    • 主要发展状况
  • DuPont de Nemours, Inc.
  • Freudenberg Group（Freudenberg Medical）
  • REHAU Group（Raumedic AG）
  • Genstar Capital LLC（TekniPlex）
  • Holland Applied Technologies, Inc.
  • Sartorius AG
  • Saint-Gobain
  • Ami Polymer
  • Nordson Corporation

第12章 附录

简介目录
Product Code: MD4254

Market Overview

The global biopharmaceutical tubing market reached US$ 3,580.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,674.2 million by 2030. The biopharmaceutical tubing market is expected to exhibit a CAGR of 8.3% during the forecast period (2023-2030). The launch and use of platinum-cured silicone tubing as a material of choice will likely emerge as a significant trend in the biopharmaceutical tuning market during the forecast period.

Thus, the players have significant opportunities to enter the biopharmaceutical tubing market with superior and cost-effective products. For instance, in January 2020, Watson-Marlow Fluid Technology Group (WMFTG) launched BioPure silicone transfer tubing to confer safe, reliable, and cost-effective solutions for a wide range of bioprocess fluid transfer applications.

Biopharmaceutical tubing is tear-resistant that is translucent. It is designed for use in manufacturing procedures for pharmaceutical and biotechnology products. Tubing utilized in pharmaceutical or biotech applications has certain specifications. When using extractable compounds, the capacity to endure sterilizing procedures and the transmission of positive test results.

The biopharmaceutical tubing market growth rate is high, owing to several factors including the rising adoption of silicone biopharmaceutical tubing due to the number of advantages these have over other materials, such as its ease of sterilization, inherent purity, pliability, and no side effects. The biopharmaceutical tubing market scope includes the type of biopharmaceutical tubing which include silicone, metal, or plastic or the applications of these tubing in various fields such as pharmaceutical and biopharmaceutical, clinical or research and development.

Market Dynamics

The increasing elderly population and strategic initiatives drive the growth of the biopharmaceutical tubing market

The global market for biopharmaceutical tubing is expanding as a result of the rising elderly population. The increase in life expectancy is leading to a rise in the geriatric population in the world. According to the World Health Organization (WHO), the global population share of people with age more than 60 would nearly double from 12% in 2015 to 22% in 2050.

According to the United Nations World Population Ageing Report, in 2017, there were 962 million people with age 60 or above in the world, and the number is expected to reach ~2.1 billion by 2050.

Additionally, strategic initiatives such as product launches, acquisitions, mergers, partnerships, or others will also provide lucrative growth to the market. For instance, in April 2021, concerning the potential of BioCardia Helix catheter biotherapeutics delivery products, BioCardia, Inc., a regenerative medicine developer company, entered into a contract with one of the top Japanese biotechnology firms. It is a non-exclusive, global license for the delivery of biotherapeutics using the BioCardia Helix catheter in particular cell types for cardiac reasons.

For manufacturers, the expanding R&D and technical breakthroughs open very significant expansion opportunities. Biopharmaceutical tubing has a huge biopharmaceutical tubing market opportunity since pharmaceutical and biopharmaceutical industries are increasingly using it to transport their substances or materials.

The growing research and development and technological advancements create lucrative growth prospects for manufacturers

There is a sizable market opportunity for biopharmaceutical tubing, as it is becoming more widely accepted in pharmaceutical and biopharmaceutical companies for the transportation of their compounds or materials. Manufacturers are going to have profitable choices for growth as demand for products like silicone or metal biopharmaceutical tubing will be required.

Silicone tubing and hoses can be used to convey the typical chemicals used in biopharmaceutical CIP (clean-in-place) or SIP (sterilize-in-place) operations. Tubing employed in pharmaceutical as well as biotech applications has certain specifications. The various varieties of silicone tubing are now being researched and developed, but before that can happen, the product must first satisfy the standards for usage in the medical industry, including non-toxicity and cleanliness.

Medical-grade silicone tubing attributes compound compositions that make it odorless, non-toxic, and tasteless. It must not have any tendency that supports bacterial growth. Hence, rising technological advancements or research and development are contributing to the growth of the market.

The disadvantages or limitations associated with the use of biopharmaceutical tubing

When processing products that contain any animal ingredients or compounds derived from animals, the majority of pharmaceutical and biopharmaceutical firms have encountered issues linked to animal ingredients and their possible effects on completed products. Tubing materials can occasionally react with industrial compounds.

Another potentially dangerous material is silicone oils. A residue may be left in the completed product as a result of the oils reacting with other ingredients. Poor welding and inner tube surfaces are the main causes of corrosion/contamination issues in pharmaceutical and biotech operations.

Given that the tubes and fittings make up 90% of the surface area in contact with the product fluid, these parts must be manufactured to make high-quality welding simple and consistent to ensure trouble-free manufacturing.

For more details on this report - Request for Sample

COVID-19 Impact Analysis

The COVID-19 analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to pricing dynamics (including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply due to trading restrictions, lockdown, and afterwards issues), government initiatives (initiatives to reactivate a market, industry, or sector by government bodies), and manufacturers strategic initiatives.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global biopharmaceutical tubing market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global biopharmaceutical tubing market growth over the forecast period.

Segment Analysis

The global biopharmaceutical tubing market is segmented based on type, application and region.

Pharmaceutical and biopharmaceutical segment account for 50.8% of the biopharmaceutical tubing market share, owing to rising demand for tubing in biopharmaceuticals.

The pharmaceutical and biopharmaceutical industry is currently growing due to huge demands owing to the increasing population. Various product launches and formulations are taking place to meet the demand for several products utilizing biopharmaceutical tubing due to its various advantages and characteristics crucial for manufacturing.

Specialized tubing with high quality is crucial for designing an efficient pharmaceutical and biopharmaceutical system for fluid processing. One must take special considerations to avoid possible product contamination found within specific tube composites as residues.

Pharmaceutical and biopharmaceutical manufacturing usually involves batch sample retention and producing drug or substance specimens. These samples (liquid) are continuously stored in small bags with tubing attached. This tubing should be sealed permanently without breaking sterility, using heat and compression to prevent contamination and spillage.

Various key players are developing and launching novel products with the latest innovations. For instance, on May 18, 2022, Freudenberg Medical, a biopharmaceutical and clinical tubing and components manufacturer, introduced its high-purity thermoplastic elastomer tubing HelixFlex, developed for different biopharmaceutical and pharmaceutical applications.

Geographical Analysis

North America holds 40.1% of the market share owing to the strong presence of major players and increasing technological advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for biopharmaceutical tubing for several operations in bioprocessing and storage in North America. The area has many producers and suppliers, and its rapid economic development has increased the industrial production of biopharmaceutical tubing, which has increased the demand.

Growth is also fueled by rising technological advancements and novel product launches. For instance, the AdvantaPURE product portfolio of biopharmaceutical tubing includes various options in its series AdvantaFlex or AdvantaSil. It includes biopharmaceutical pump tubing, platinum-cured silicone tubing and reinforced tubing, and reinforced FEP, PTFE, and EPDM tubing.

AdvantaPURE develops tubing for different needs, such as high-pressure silicone tubing, low-temperature silicone tubing, and tubing specifically developed for the durability of pumping systems and tubing which enhance the pressure capabilities. The aforementioned elements show North America's supremacy on a worldwide scale.

Competitive Landscape

The major global players in the biopharmaceutical tubing market include W. L. Gore and Associates, Inc., Rehu Group (RAUMEDIC AG), Freudenberg Group (Freudenberg Medical), Genstar Capital (Tekni-Plex, Inc.), Holland Applied Technologies, Inc., DuPont de Nemours, Inc., Sartorius AG, Ami Polymer, Saint-Gobain and Nordson Corporation among others.

Why Purchase the Report?

  • To visualize the global biopharmaceutical tubing- market segmentation based on type, application and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of biopharmaceutical tubing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global biopharmaceutical tubing market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Elderly Population and Strategic Initiatives
      • 4.1.1.2. Growing Application of Single-Use Systems (SUS)
    • 4.1.2. Restraints
      • 4.1.2.1. The Disadvantages or Limitations Associated With the Use of Biopharmaceutical Tubing
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Silicone *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Plastic
  • 7.4. Metal

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Pharmaceutical and Biopharmaceutical *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinical
  • 8.4. Research and Development
  • 8.5. Diagnosis

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. The U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. W. L. Gore and Associates, Inc. *
    • 11.1.1. Company Overview
    • 11.1.2. Type Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. DuPont de Nemours, Inc.
  • 11.3. Freudenberg Group (Freudenberg Medical)
  • 11.4. REHAU Group (Raumedic AG)
  • 11.5. Genstar Capital LLC (TekniPlex)
  • 11.6. Holland Applied Technologies, Inc.
  • 11.7. Sartorius AG
  • 11.8. Saint-Gobain
  • 11.9. Ami Polymer
  • 11.10. Nordson Corporation

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us